MERCK & CO. INC. (MRK)       102.94  -0.52 (-0.5%)

102.94  -0.52 (-0.5%)

US58933Y1055 - Common Stock - After market: 102.93 -0.01 (-0.01%)

MERCK & CO. INC.102.94

NYSE:MRK (2/3/2023, 7:04:00 PM)-0.52 (-0.5%)

After market: 102.93 -0.01 (-0.01%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Pharmaceuticals

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 02-02 2023-02-02/amc Earnings (Next) 04-27 2023-04-27/amc
Ins Owners 0.06% Inst Owners 74.25%
Market Cap 260.99B Shares 2.54B
PE 13.44 Fwd PE 13.5
Dividend Yield 2.66% Analysts 78.75
IPO 01-01 1941-01-01

Stock Screener Links

Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

MRK Daily chart

Company Profile

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Kenilworth, New Jersey and currently employs 68,000 full-time employees. The firm offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. The company operates through two segments: Pharmaceutical and Animal Health. The firm's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The firm sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species.

Company Info

MERCK & CO. INC.

2000 Galloping Hill Road

Kenilworth NEW JERSEY 07033

P: 19087404000.0

CEO: Kenneth C. Frazier

Employees: 68000

Website: https://www.merck.com/

MRK News

News Imagea day ago - Investor's Business DailyMarket Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review

The major indexes continued to run despite mixed-to-weak earnings.

News Image2 days ago - Seeking AlphaMerck Keytruda shows survival benefit in uterus cancer, meeting main goal of phase 3 trial

Merck's (MRK) blockbuster drug Keytruda, with chemotherapy, met the main goal of progression free survival ((PFS)) in patients with a type of cancer of the uterus in a phase 3...

News Image2 days ago - Merck & Co., Inc.Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial CarcinomaNews Image2 days ago - Seeking AlphaMeta drives surge in Nasdaq and S&P 500; Dow slips

An earnings-inspired rally in Meta Platforms (META) fueled gains in the Nasdaq and S&P 500 on Thursday, adding to Fed-related gains registered the day before

News Image2 days ago - InvestorPlaceThe 7 Most Undervalued Dow Stocks to Buy in February 2023

If you’re looking for the best deals among the most iconic enterprises, these are the most undervalued Dow stocks to buy.

News Image2 days ago - The Motley FoolMerck (MRK) Q4 2022 Earnings Call Transcript

MRK earnings call for the period ending December 31, 2022.

MRK Twits

Here you can normally see the latest stock twits on MRK, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example